This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Acousia Therapeutics ACOU085 Phase 2a Results
Tech clinical trial results

Acousia Therapeutics ACOU085 Phase 2a Results

Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
70
Attention
6
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 2a clinical trial results for ACOU085 by Acousia Therapeutics GmbH are expected to generate significant interest in the biotechnology and pharmaceutical sectors. This could lead to increased investment and potential partnership opportunities for Acousia Therapeutics GmbH, especially given the unmet medical need for preventing cisplatin-induced hearing loss.

Biotechnology Pharmaceuticals
Event Summary

Acousia Therapeutics GmbH, a clinical-stage biotechnology company, announced positive top-line efficacy results from its Phase 2a PROHEAR Study for ACOU085 (Bimokalner). The study assessed the otoprotective efficacy of ACOU085 in testicular cancer patients at risk of cisplatin-induced sensorineural hearing loss. Results showed a clinically meaningful prevention of pure-tone audiometry threshold increases at affected frequencies compared to placebo. This milestone is seen as an important step towards establishing Kv7.4 activation as a novel therapeutic approach for hearing loss. Acousia Therapeutics GmbH plans to attend the Cape Town International Convention Centre to discuss collaboration opportunities for the next phase of clinical development.

Entities Involved
priv
Acousia Therapeutics
Acousia Therapeutics GmbH announced positive top-line efficacy results from its Phase 2a PROHEAR Study for ACOU085, which could lead to further clinical development and potential collaborations.
Importance 100.0 Sentiment 75.0
oth
ACOU085
ACOU085 (Bimokalner) is the drug candidate developed by Acousia Therapeutics GmbH that showed clinically meaningful prevention of hearing loss in the PROHEAR Study.
Importance 90.0 Sentiment 70.0
per
Tim Boelke
Tim Boelke, CEO & CMO of Acousia Therapeutics GmbH, highlighted the potential of ACOU085 to prevent permanent inner ear damage.
Importance 50.0 Sentiment 60.0
per
Hubert Löwenheim
Professor Hubert Löwenheim, Scientific Supervisor of the PROHEAR Study, commented on the encouraging milestone for Kv7.4 activation as a therapeutic approach for hearing loss.
Importance 40.0 Sentiment 60.0
loc
United States — San Diego
United States — San Diego is the location for the Cape Town International Convention Centre where Acousia Therapeutics GmbH will seek strategic partners.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.